TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
Shaveta Vinayak(Roswell Park Comprehensive Cancer Center), Melinda L. Telli(Stanford University), Carey K. Anders(Duke University), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), Gerburg M. Wulf(Beth Israel Deaconess Medical Center), Antoinette R. Tan(Wake Forest University), Georgia A. McCann(The Ohio State University Wexner Medical Center), Haroun Achour(Tesaro (United States)), Nathan Buerstatte(Massachusetts General Hospital), John K. Erban(Tufts University), Sara M. Tolaney(Harvard University), Patrick M. Dillon(University of Virginia), Lee S. Schwartzberg(Renown Health), Corrine Zarwan(Beth Israel Deaconess Medical Center), Yinghui Zhou(Second Xiangya Hospital of Central South University), Monica Mita(Novartis (Switzerland)), Bruce J. Dezube(Xilio Therapeutics (United States)), Filipa Lynce(Institut Claudius Regaud), Sujata Arora(Tesaro (United States)), Andres Forero‐Torres(Kirklin Clinic)
Cited by 77
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k